On 4 November 2026, Sisram Medical Ltd conducted an on-market buyback of 50,000 ordinary shares on the Stock Exchange of Hong Kong under the general mandate granted on 24 June 2026.

The shares were repurchased at prices ranging between HKD 1.77 and HKD 1.82, at a volume-weighted average cost of HKD 1.8079 per share. Total consideration amounted to approximately HKD 0.09 million.

Following the transaction, Sisram’s issued share capital (excluding treasury shares) declined by 0.011% to 467.46 million shares. Treasury shares increased from 833,200 to 883,200, while the company’s total issued share count remained unchanged at 468.34 million.

Cumulatively, Sisram has repurchased 883,200 shares—equivalent to 0.189% of the shares outstanding on the date the mandate was granted—against the authorised limit of 46.83 million shares. No repurchased shares have been cancelled; all are held in treasury.

Under listing rules, Sisram is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 December 2026.